Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
Pharming Group (Nasdaq: PHAR) announced its participation in the upcoming H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharming Group (Nasdaq: PHAR) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York, scheduled for September 8-10, 2025. CEO Fabrice Chouraqui will deliver a presentation on Monday, September 8 at 1:30pm EDT/19:30 CEST.
Investors can access the live webcast and replay through Pharming's website in the "Upcoming Events" and "News" sections. One-on-one meetings with management can be arranged through Investor Relations or H.C. Wainwright representatives.
Details
News Market Reaction – PHAR
On Sep 3, the day this news came out, PHAR closed 2.50% above the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025.
Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 8 at 1:30pm EDT/19:30 CEST. A live webcast and replay of the presentation can be found in the “Upcoming Events” and “News” sections of Pharming’s website.
For more information about the conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Investor Relations at investor@pharming.com or your H.C. Wainwright representative.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
FTI Consulting, London, United Kingdom
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
US PR
Ethan Metelenis
T: +1 (917) 882-9038
E: Ethan.Metelenis@precisionaq.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.